From licensing activity to pricing behavior, three emerging patterns from 2025 offer a clearer picture for the New Year.

Held back for decades, cannabis research is a central part of marijuana rescheduling. But some questions remain.

Cannabis investors may be feeling bullish entering 2026 after marijuana rescheduling, but some more advances are needed for ...

Marijuana rescheduling isn't official yet. Here's what needs to happen for cannabis to be downgraded under federal law.

Cannabis business owner Wanda James is singing a familiar tune – one that fans of Jamaican reggae singer Peter Tosh know well: “Legalize it.” ...

The Cannabist Co. will sell its vertically integrated permit in Virginia to a Boston-based hedge fund rather than competing ...

The U.S. cannabis industry continued to pullback in the third quarter of 2025, according to licensing data from intelligence ...

Cannabis' sworn enemy revealed itself to be behind the voter initiative campaigns seeking to roll back $1.9 billion in annual sales.

President Donald Trump's order to reclassify cannabis as a Schedule 3 drug is a huge step forward - but operators must know its limits.

Cannabis will be moved to Schedule 3 of the Controlled Substances Act under an executive order President Donald Trump signed Thursday.

With President Donald Trump’s executive order to reschedule cannabis, businesses in the industry are rolling out their growth strategies.

New Jersey legislators are moving forward with a bill that could reshape the state’s market for hemp-derived cannabinoids.